Share: Facebook Twitter LinkedIn
Activity Provided By:

i3 Health

Leveraging the Growing Arsenal of Adjuvant Therapies for Early-Stage NSCLC

Access Activity

Overview / Abstract:

In this activity, Dr. Helena A. Yu, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, will provide insights into strategies for leveraging the growing arsenal of adjuvant therapies for early-stage non"small cell lung cancer (NSCLC), including treatment selection and adverse event management. Start the activity now!


Lung cancer is the second most commonly diagnosed cancer and the leading cause of death for men and women worldwide. In the United States, non"small cell lung cancer (NSCLC) accounts for 81% of all lung cancer diagnoses (, 2023). Therapeutic options, survival rates, and outcomes for NSCLC are dramatically impacted by disease stage. For patients with early-stage disease, radical surgery is the mainstay of treatment; however, patients have a significant risk of relapse following surgery and local treatment. Numerous novel therapeutic approaches, including the use of molecular biomarkers and the development of targeted agents and immune checkpoint inhibitors, are under investigation for early-stage NSCLC, contributing to a growing arsenal of treatment options for this disease (Indini et al, 2020). In this activity, Helena A. Yu, MD, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, will provide expert perspectives on diagnosis, identification of biomarkers, and efficacy and safety data of novel adjuvant therapies to improve survival outcomes for patients with early-stage NSCLC.


Medical oncologists, radiation oncologists, surgical oncologists, pulmonologists, nurse practitioners, physician assistants, oncology nurses, and other health care professionals involved in the treatment of patients with non"small cell lung cancer (NSCLC).


Upon completion of this activity, participants should be able to

-Identify the correct tumor stage and appropriate management approach for NSCLC based on the latest evidence
-Distinguish biomarkers for early-stage NSCLC that can inform individualized treatment strategies
-Appraise efficacy and safety data of novel adjuvant therapies for patients with NSCLC as elucidated by recent clinical trials
-Apply strategies to prevent and mitigate adverse events associated with novel adjuvant therapies for early-stage NSCLC


Jul 31, 2024


Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME


Webinar / Webcast / Video

Credits / Hours

1.0 CME | 1.0 NCPD | MOC | ILNA



Presenters / Authors / Faculty

Helena A. Yu, MD
Associate Attending Physician
Memorial Sloan Kettering Cancer Center

Sponsors / Supporters / Grant Providers

This activity is supported by an independent educational grant from Merck.

Keywords / Search Terms

i3 Health NSCLC, Non-Small Cell Lung Cancer, Pulmonology, Oncology, i3 Health, CME, NCPD, free CNE, free NCPD, Free CE, Free CME, Nursing, Oncology Nursing, Physician, Oncology Physician, Lung Cancer Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map